Medical Design Briefs - November 2021 - 10

HONORABLE MENTIONS
First-in-Class Therapeutic Pain Drug Designed from Proteins
Samerender Nagam Hanumantharao, Research Scientist, Neurocarrus Inc.
Derek Allen, PhD student, University of Nebraska - Lincoln
Paul Blum, CEO and Founder, Neurocarrus Inc.
he opioid crisis is a major
epidemic. Social and economic
well-being have flatlined
as opioid abuse and overdoses
devastate communities and
overwhelm public health infrastructure.
According to the CDC,
almost 136 people die every day
in the United States due to an
opioid overdose. Starting in the
1990s in the United States, an
uptick in opioid prescriptions for
managing pain led to increased
opioid dependence, especially in
people suffering from chronic
pain. The increase in injection
pain drugs have also led to a
deadly syndemic with HIV and
Hepatitis C across the world.
Hence, there have been multiple
efforts to control the crises and
has accelerated research efforts
into developing non-opioid
based medications for treating
and managing pain.
T
C2C pain drug
Reduces pain
like behavior by
7x
Non-Addictive
Neurocarrus Inc. has developed
a groundbreaking drug to
easily treat localized pain without
side effects. C2C is a novel protein
drug designed and engineered
by Neurocarrus re -
searchers from natural
proteins to be a longlasting,
local painkiller.
C2C specifically targets
only the pain neurons
and hence does not
affect muscular activity.
This specific mode of
action
is unique for
treating pain and is
also nonaddictive. Pre -
clinical trials have
demonstrated the pain
reduction to be almost
C1 Binding domain
seven times more and 20 times longer
than the currently prescribed over-thecounter
pain relievers and narcotic pain
medications, thus reducing the need for
frequent injections.
The preliminary pain tests performed
on animals have also confirmed its efficacy
to control inflammatory pain and
surgical pain. These tests also demonstrated
that C2C was safer for multiple
uses compared to opioids that can cause
addiction and provided stronger pain
10
Cov
Works 20×
longer than
Anesthesia
No side effects
C2C Drug Structure
C2I payload
Adapter
C2II
Translocation
domain
relief than anesthesia,
ibuprofen, and other overthe-counter
pain medications.
The drug C2C also
did not cause any side
effects in long-term toxicity
studies performed in
animals as compared to
the addiction, drowsiness,
constipation, nausea, and
breathing troubles caused by opioid
medications.
The efficiency of the drug has also
independently been corroborated by
multiple U.S. federal agencies. C2C does
not use any animal by-products. The
purity and efficiency of drug C2C are
ensured through multiple postprocessing
and testing steps to ensure the highest
standards of manufacturing. C2C
production can be scaled up easily and
has already received support through
www.medicaldesignbriefs.com
ToC
the Nebraska Department of Economic
Development for mass production.
Neurocarrus has an exclusive license on
the patent for C2C for all fields of use in
seven jurisdictions. The project has also
received backing from the National
Institutes of Health (NIH) through the
Helping to End Addiction Long-term
(HEAL)
initiative, as well as private
investors. The developers have a team
comprised of prominent research scientists
in the field of protein engineering,
which is led by a strong management
team with expertise in business, biotechnology,
and medicine. With a mission to
" Transform the Way We Treat Pain, " the
company seeks to improve healthcare
and help control the opioid epidemic
across the world by providing a safer
alternative to the prescription of opioids
as pain medications, especially among
people suffering from chronic pain.
Medical Design Briefs, November 2021
http://www.medicaldesignbriefs.com
Medical Design Briefs - November 2021

Table of Contents for the Digital Edition of Medical Design Briefs - November 2021
